Logo

LEXX

Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp. • NASDAQ
$1.09 ▼ -2.68% (-0.03)
Market Cap $19.73 M
52w High $2.85
52w Low $0.78
Dividend Yield 0%
P/E -1.6
Volume 50.50K
Outstanding Shares 18.10M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $174K $3.924M ▲ $-3.789M ▼ -2.178K% ▼ $-0.21 ▼ $-3.719M ▼
Q2-2025 $174K ▼ $2.925M ▲ $-2.713M ▼ -1.559K% ▼ $-0.15 ▲ $-2.749M ▼
Q1-2025 $183.923K ▲ $2.872M ▲ $-2.704M ▼ -1.47K% ▲ $-0.16 ▲ $-2.658M ▼
Q4-2024 $84K $2.287M ▲ $-2.185M ▼ -2.601K% ▼ $-0.17 ▼ $-2.202M ▼
Q3-2024 $84K $1.827M $-1.782M -2.121K% $-0.13 $-1.728M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.625M ▼ $6.741M ▼ $1.575M ▼ $5.552M ▼
Q2-2025 $6.543M ▼ $8.678M ▼ $1.917M ▲ $7.145M ▼
Q1-2025 $8.118M ▲ $9.794M ▲ $399.718K ▼ $9.774M ▲
Q4-2024 $6.556M ▼ $8.868M ▼ $1.209M ▲ $8.036M ▼
Q3-2024 $8.505M $10.018M $271.375K $10.123M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.791M ▼ $-3.584M ▼ $-19.443K ▲ $1.689M ▲ $-1.877M ▼ $-3.584M ▼
Q2-2025 $-2.717M ▼ $-1.498M ▲ $-27.894K ▲ $11.72K ▼ $-1.609M ▼ $-1.498M ▲
Q1-2025 $-2.707M ▼ $-2.726M ▼ $-37.804K ▲ $4.345M ▲ $1.578M ▲ $-2.726M ▼
Q4-2024 $-2.192M ▼ $-1.892M ▼ $-69.587K ▼ $0 ▼ $-1.959M ▼ $-1.961M ▼
Q3-2024 $-1.782M $-1.266M $-22K $5.043M $3.754M $-1.288M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025Q4-2025
B2B
B2B
 $0 ▲$0 ▲$0 ▲$0 ▲
IP Licensing
IP Licensing
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Lexaria is a classic early‑stage biotech: essentially no meaningful revenues yet and recurring net losses each year. The income statement shows a research‑driven company still in the development and validation phase, not in commercial scale-up. Losses appear relatively small in absolute terms, but there is no operating income to offset them, so the business remains fully dependent on external funding rather than internally generated profits. Earnings per share have been negative and somewhat volatile, which is typical for a company moving through R&D cycles and capital raises without product launches yet.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a modest base of assets and equity and almost everything concentrated in cash and equivalents. Importantly, the company carries essentially no financial debt, which reduces balance‑sheet risk but also highlights that its investment capacity is limited by its small capital base. Overall, this looks like a lean, asset‑light biotech platform rather than a company with heavy physical infrastructure. The flip side is that any setback in funding or partnering could quickly pressure this small balance sheet.

Cash Flow

Cash Flow Cash flows reflect a business that is investing in development without bringing in commercial cash yet. Operating cash flow is modestly negative, and free cash flow is consistently in the red, driven by ongoing R&D and operating costs rather than large capital expenditures. In simple terms, money is flowing out to fund science and trials, not yet flowing in from products or licensing at scale. This pattern is common for small biotech firms but means the company remains reliant on raises, grants, or partnership payments to sustain operations.

Competitive Edge

Competitive Edge Lexaria’s edge is not a specific drug, but its DehydraTECH drug‑delivery platform, which aims to make oral versions of challenging molecules more effective, faster‑acting, and better tolerated. Its main competitive strengths are a broad patent portfolio across major markets and the flexibility to apply the technology to many therapeutic areas, from weight‑loss and diabetes drugs (GLP‑1s) to hypertension, epilepsy, antivirals, and nicotine. This positions the company as a potential partner to larger pharma firms rather than a head‑to‑head competitor with them. The main competitive risks are the early stage of clinical validation, the presence of alternative delivery technologies from much larger players, and the need to secure strong, visible licensing deals to prove real-world commercial traction.

Innovation and R&D

Innovation and R&D Innovation is the core of Lexaria’s story. DehydraTECH is designed to boost oral absorption, speed onset, reduce side effects, and even mask unpleasant tastes, which can be very attractive for both patients and drug makers. The company is focusing R&D on high‑profile areas like GLP‑1 drugs for diabetes and obesity, where oral alternatives to injections could be especially valuable. Early studies suggest promising signals—such as higher drug levels in the blood and fewer side effects compared with existing oral options—but these are still early-stage results that must be confirmed in larger, longer trials. Beyond GLP‑1s, the platform is being explored in blood pressure, epilepsy, nicotine delivery, and antivirals, which could diversify future opportunities if the science continues to hold up. Overall, Lexaria is long on scientific optionality and patents, but still short on late‑stage data and commercial proof.

Summary

Lexaria Bioscience is a small, pre‑revenue biotech platform company built around a patented oral drug‑delivery technology rather than a conventional product lineup. Financially, it has minimal revenue, recurring but relatively modest losses, a slim, mostly cash-based balance sheet, and negative cash flow typical of early‑stage R&D firms, with no debt but clear dependence on external funding. Strategically, its strength lies in the DehydraTECH platform, a sizable global patent estate, and the ability to target multiple high‑value therapeutic areas through licensing partnerships. The key uncertainties are whether upcoming clinical trials—especially in GLP‑1 weight‑loss and diabetes drugs—will produce strong, reproducible results, and whether Lexaria can convert that into meaningful alliances and eventual royalty streams before its limited financial resources are stretched. In short, this is a high‑innovation, high‑execution‑risk profile, where future value rests heavily on R&D milestones and partnership success rather than current financial performance.

NEWS

November 12, 2025 · 9:10 AM UTC

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Read more

October 9, 2025 · 9:20 AM UTC

Lexaria Bioscience Corp. Provides Strategic Update

Read more

September 29, 2025 · 4:30 PM UTC

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read more

September 26, 2025 · 8:00 AM UTC

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read more

September 19, 2025 · 11:20 AM UTC

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Read more